Janney Capital downgraded Clovis Oncology Inc (NASDAQ:CLVS) from Buy to Neutral in a report released today.
- Updated: September 21, 2016
Just yesterday Clovis Oncology Inc (NASDAQ:CLVS) traded 0.00% even at $35.68. Clovis Oncology Inc’s 50-day average is $22.24 and its two hundred day average is $17.16. With the last stock price close up 102.93% relative to the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. Trade Volume was down over the average, with 42,608 shares of CLVS changing hands under the typical 2,264,320
Janney Capital has downgraded Clovis Oncology Inc (NASDAQ:CLVS) from Buy to Neutral in a statement released on 9/21/2016.
On Wednesday August 24, 2016, Mizuho Securities reported on Clovis Oncology Inc (NASDAQ:CLVS) upped the target price from $15.00 to $23.00 that suggested a downside of 0.00%.
See Chart Below
With a total market value of $0, Clovis Oncology Inc has with a 52 week low of $11.57 and a 52 week high of $109.18 .
A total of 8 brokerages have issued a research note on CLVS. 2 firms rating the stock a strong buy, zero equity analysts rating the company a buy, 6 brokers rating the stock a hold, 0 brokerages rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $17.50.
More About Clovis Oncology Inc (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.